Can a new migraine drug stop the dizzy spells?

NCT ID NCT07751497

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether rimegepant, a newer migraine medication, works as well as flunarizine, an older preventive, for reducing days with moderate-to-severe dizziness in people with vestibular migraine. About 400 adults aged 18 to 75 will take one of the two drugs daily for 12 weeks and track their symptoms in a diary. The goal is to see if rimegepant can match flunarizine in cutting down the number of dizzy days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rimegepant (a CGRP-blocking drug) compared with flunarizine (a calcium-channel blocker)
What this could lead to
If rimegepant proves as good as flunarizine, it could offer a newer, potentially better-tolerated option to prevent dizzy spells in people with vestibular migraine.
What could go wrong
This is a phase 2 trial, so results are preliminary. Rimegepant might not match flunarizine's effectiveness, and side effects could differ. The open-label design (participants know their treatment) may also bias results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VESTIBULAR MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88 Jiefang Road

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.